A novel method of luteal supplementation with recomb gonadotropin-releasing hormone agonist is used instea gonadotropin for ovulation triggering: a randomized pr

Fertility and Sterility

95, 1174-1177

DOI: 10.1016/j.fertnstert.2010.09.023

Citation Report

#	Article	IF	Citations
1	Endocrine disorders & female infertility. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 861-873.	2.2	129
2	Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormoneÂagonist. Fertility and Sterility, 2011, 96, 63-68.	0.5	41
3	New algorithm for OHSS prevention. Reproductive Biology and Endocrinology, 2011, 9, 147.	1.4	63
4	GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study. Human Reproduction, 2011, 26, 2874-2877.	0.4	54
5	Reply: GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. Human Reproduction Update, 2012, 18, 229-230.	5.2	2
6	GnRH agonist for triggering final oocyte maturation: time for a critical evaluation of data. Human Reproduction Update, 2012, 18, 228-229.	5.2	11
7	Should Cochrane reviews be performed during the development of new concepts?. Human Reproduction, 2012, 27, 6-8.	0.4	11
8	The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reproductive BioMedicine Online, 2012, 24, 134-141.	1.1	89
9	Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help?. Reproductive BioMedicine Online, 2012, 24, 680-681.	1.1	21
10	Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertility and Sterility, 2012, 97, 1316-1320.	0.5	132
11	Prevention and management of ovarian hyperstimulation syndrome. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 817-827.	1.4	16
12	The gonadotropinâ€releasing hormone antagonist protocol â€“ the protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. Acta Obstetricia Et Gynecologica Scandinavica, 2012, 91, 643-647.	1.3	12
13	Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormoneâ€“gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertility and Sterility, 2013, 100, 742-747.e1.	0.5	74
14	Treatment of Luteal Phase Defects in Assisted Reproduction. Current Drug Targets, 2013, 14, 832-842.	1.0	8
15	Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertility and Sterility, 2013, 100, 1296-1302.	0.5	121
16	Ovarian Hiperstimulation Syndrome: incidence in a public service of assisted reproduction and literature review. Reproducao E Climaterio, 2013, 28, 10-17.	0.1	2
17	GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Human Reproduction, 2013, 28, 2511-2521.	0.4	197
18	Pratique de la stimulation ovulatoire par les gonadotrophines. , 2013, , .		1

#	Article	IF	Citations
19	Low-dose hCG supplementation after GnRH agonist triggering: don't be too quick on the trigger. Human Reproduction, 2013, 28, 2315-2317.	0.4	17
20	The Use of Corifollitropin Alfa in Combination with a GnRH Analogue as Final Trigger in the Potential High Responders. Journal of Fertilization in Vitro IVF Worldwide Reproductive Medicine Genetics & Stem Cell Biology, 2014, 03, .	0.2	0
21	British Fertility Society Policy and Practice Committee: Prevention of Ovarian Hyperstimulation Syndrome. Human Fertility, 2014, 17, 257-268.	0.7	23
22	Pharmaceutical Options for Triggering of Final Oocyte Maturation in ART. BioMed Research International, 2014, 2014, 1-7.	0.9	40
23	Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. The Cochrane Library, 2014, 2014, CD008046.	1.5	196
24	Best Protocol for Controlled Ovarian Hyperstimulation in Assisted Reproductive Technologies: Fact or Opinion?. Seminars in Reproductive Medicine, 2014, 32, 262-271.	0.5	21
25	Gonadotrophins: The future. Journal of Human Reproductive Sciences, 2014, 7, 236.	0.4	14
26	Impact of final oocyte maturation using gonadotropin-releasing hormone agonist triggering and different luteal support protocols on endometrial gene expression. Fertility and Sterility, 2014, 101, 138-146.e3.	0.5	25
27	GnRHa trigger for final oocyte maturation: is HCG trigger history?. Reproductive BioMedicine Online, 2014, 29, 274-280.	1.1	45
28	Fresh versus frozen embryo transfer: backing clinical decisions with scientific and clinical evidence. Human Reproduction Update, 2014, 20, 808-821.	5.2	249
29	GnRH Agonist Triggers and their Use in Assisted Reproductive Technology: The Past, the Present and the Future. Women's Health, 2014, 10, 267-276.	0.7	12
30	Improving the luteal phase after ovarian stimulation: reviewing new options. Reproductive BioMedicine Online, 2014, 28, 552-559.	1.1	76
31	Luteal phase support for assisted reproduction cycles. The Cochrane Library, 2016, 2016, CD009154.	1.5	215
32	Contribution to More Patient-Friendly ART Treatment: Efficacy of Continuous Low-Dose GnRH Agonist as the Only Luteal Supportâ€"Results of a Prospective, Randomized, Comparative Study. International Journal of Endocrinology, 2015, 2015, 1-10.	0.6	37
33	Luteinizing hormone and human chorionic gonadotropin: a review of their varied clinical applications in assisted reproductive technology. Expert Review of Endocrinology and Metabolism, 2015, 10, 87-100.	1.2	4
34	A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation. Taiwanese Journal of Obstetrics and Gynecology, 2015, 54, 583-587.	0.5	5
35	GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: Systematic review and meta-analysis. Journal of Advanced Research, 2015, 6, 341-349.	4.4	23
36	Luteal phase supplementation afterÂgonadotropin-releasing hormone agonist trigger in fresh embryo transfer: the American versus European approaches. Fertility and Sterility, 2015, 103, 879-885.	0.5	61

#	Article	IF	Citations
37	Ovulation Stimulation with Gonadotropins. , 2015, , .		1
39	Controlled Ovarian Stimulation for Follicular Recruitment and Oocyte Recovery in IVF. , 2015, , 21-31.		0
44	Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome. Gynecological Endocrinology, 2015, 31, 693-697.	0.7	10
45	Micro-dose hCG as luteal phase support without exogenous progesterone administration: mathematical modelling of the hCG concentration in circulation and initial clinical experience. Journal of Assisted Reproduction and Genetics, 2016, 33, 1311-1318.	1.2	29
46	An update on the prevention of ovarian hyperstimulation syndrome. Women's Health, 2016, 12, 496-503.	0.7	13
47	The impact of using gonadotropin-releasing hormone agonist for triggering final oocyte maturation in antagonist-treated intracytoplasmic sperm injection cycles on women at high risk of developing ovarian hyperstimulation syndrome. Evidence Based Women S Health Journal, 2016, 6, 85-89.	0.0	0
48	Lutealâ€phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study. Clinical Endocrinology, 2016, 84, 720-728.	1.2	75
49	GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reproductive BioMedicine Online, 2016, 32, 274-285.	1.1	86
50	Gonadotropin-releasing hormoneÂagonist trigger in oocyteÂdonors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study. Fertility and Sterility, 2016, 105, 356-363.	0.5	52
51	Gonadotropin-releasing hormone agonist (GnRHa) trigger â€“ State of the art. Reproductive Biology, 2017, 17, 1-8.	0.9	51
52	Prediction and Prevention of Ovarian Hyperstimulation Syndrome. , 0, , 124-140.		1
53	Elimination of OHSS by GnRH Agonist and Freezing Embryos. , 0, , 149-163.		4
54	Gonadotropin-Releasing Hormoneâ€“Agonist Triggering and a Freeze-All Approach: The Final Step in Eliminating Ovarian Hyperstimulation Syndrome?. Obstetrical and Gynecological Survey, 2017, 72, 296-308.	0.2	19
55	Clinical Management of Pregnancies following ART. , 2017, , .		0
56	GnRH Agonist Trigger and LH Activity Luteal Phase Support versus hCG Trigger and Conventional Luteal Phase Support in Fresh Embryo Transfer IVF/ICSI Cyclesâ€”A Systematic PRISMA Review and Meta-analysis. Frontiers in Endocrinology, 2017, 8, 116.	1.5	56
57	Impact of Mid-Luteal Phase GnRH Agonist Administration on Reproductive Outcomes in GnRH Agonist-Triggered Cycles: A Randomized Controlled Trial. Frontiers in Endocrinology, 2017, 8, 124.	1.5	18
58	Luteal phase support after gonadotropin-releasing hormone agonist triggering: does it still matter?. Fertility and Sterility, 2018, 109, 763-767.	0.5	18
59	Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 2018, 298, 17-26.	0.8	22

#	Article	IF	Citations
60	Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial. Human Reproduction, 2018, 33, 1079-1086.	0.4	11
61	Preventing Age Related Fertility Loss. , 2018, , .		1
62	Safety of Preventive Oocyte Cryopreservation. , 2018, , 125-139.		0
63	Two Hormones for One Receptor: Evolution, Biochemistry, Actions, and Pathophysiology of LH and hCG. Endocrine Reviews, 2018, 39, 549-592.	8.9	118
64	The Ovulation: Triggering Ovulation with hCG Versus GnRH-Agonist. , 2018, , 263-267.		0
65	Ovarian Hyperstimulation Syndrome. , 2019, , 581-587.		0
66	A Rationale for Timing of Luteal Support Post Gonadotropin-Releasing Hormone Agonist Trigger. Gynecologic and Obstetric Investigation, 2019, 84, 1-5.	0.7	7
67	Common Stimulation Regimens in Assisted Reproductive Technology. , 2019, , 131-137.		0
68	Advances in ovulation trigger strategies. Panminerva Medica, 2019, 61, 42-51.	0.2	18
69	A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome. Expert Review of Endocrinology and Metabolism, 2019, 14, 315-319.	1.2	23
70	The Role of GnRH Agonist Triggering in GnRH Antagonist-Based Ovarian Stimulation Protocols. , 2019, , 363-377.		0
71	GnRH agonist triggering followed by 1500 IU of HCG 48 h after oocyte retrieval for luteal phase support. Reproductive BioMedicine Online, 2020, 41, 854-858.	1.1	6
72	Gonadotropin-releasing hormone agonist for ovulation trigger â€“ OHSS prevention and use of modified luteal phase support for fresh embryo transfer. Upsala Journal of Medical Sciences, 2020, 125, 131-137.	0.4	18
73	ESHRE guideline: ovarian stimulation for IVF/ICSIâ€. Human Reproduction Open, 2020, 2020, hoaa009.	2.3	205
74	The early luteal hormonal profile in IVF patients triggered with hCG. Human Reproduction, 2020, 35, 157-166.	0.4	33
75	Comparative study between single versus dual trigger for poor responders in GnRHâ€antagonist ICSI cycles: A randomized controlled study. International Journal of Gynecology and Obstetrics, 2021, 152, 395-400.	1.0	14
76	Angiogenic cytokine and interleukin 8 levels in early luteal phase after triggering ovulation with gonadotropinâ€releasing hormone agonist in highâ€responder patients. American Journal of Reproductive Immunology, 2021, 85, e13381.	1.2	3
77	What is the optimal luteal support in assisted reproductive technology?. Hormone Molecular Biology and Clinical Investigation, 2021, .	0.3	4

#	Article	IF	Citations
78	Time, time, time: see what governs the luteal phase endocrinology. Gynecological Endocrinology, 2021, 37, 775-777.	0.7	5
79	Gonadotropin-releasing hormone agonist (alone or combined with human chorionic gonadotropin) vs. human chorionic gonadotropin alone for ovulation triggering during controlled ovarian stimulation for inÂvitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. F&S Reviews, 2021, 2, 353-370.	0.7	4
80	HCG: Is it the Best Choice for Ovulation Triggering?. The Open Reproductive Science Journal, 2012, 4, 1-3.	0.5	3
81	GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. International Journal of Reproductive BioMedicine, 2016, 14, 557-566.	0.5	22
82	Morphological changes of gonadotropin-releasing hormone neurons in the rat preoptic area across puberty. Neural Regeneration Research, 2014, 9, 1303.	1.6	8
83	Comparison of two different dosage of GnRH agonist as ovulation trigger in oocyte donors: a randomized controled trial. Jornal Brasileiro De Reproducao Assistida, 2017, 21, 183-187.	0.3	9
84	Luteal-phase support in assisted reproductive technology: An ongoing challenge. International Journal of Reproductive BioMedicine, 2021, 19, 761-772.	0.5	9
85	Soutenir la phase lutÃ©ale. , 2013, , 77-83.		0
86	Ovarian Hyperstimulation Syndrome. , 2015, , 35-57.		0
87	Current scientific and practical luteal phase support strategies. Russian Journal of Human Reproduction, 2016, 22, 20.	0.1	1
88	Strategies for Risk Reduction and Improving Success in Women with Medical Comorbidities. , 2017, , 221-228.		0
89	Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review). Kuban Scientific Medical Bulletin, 2020, 27, 136-148.	0.1	0
90	Pharmacological Options to Trigger Final Oocyte Maturation in In Vitro Fertilization. Journal of SAFOG, 2020, 12, 38-44.	0.1	1
91	The Luteal Phase after GnRHa Trigger-Understanding An Enigma. International Journal of Fertility & Sterility, 2014, 8, 227-34.	0.2	13
92	GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. International Journal of Reproductive BioMedicine, 2016, 14, 557-566.	0.5	11
93	Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management. Iranian Journal of Medical Sciences, 2018, 43, 248-260.	0.3	35
94	Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review. Reproductive Health, 2022, 19, 19.	1.2	4
95	Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study. Frontiers in Endocrinology, 2022, 13, 826411.	1.5	4

#	Article	IF	Citations
96	Luteal Phase Support Other than Progesterone. , 2022, , 302-310.		0
97	Luteal phase support in ART programs the necessity of optimization and the importance of personalization. Russian Journal of Human Reproduction, 2022, 28, 66.	0.1	0
98	Agonist triggering in oocyte donation programsâ€"Mini review. Frontiers in Endocrinology, 0, 13, .	1.5	3
99	Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients. Frontiers in Endocrinology, 0, 13, .	1.5	0
100	Luteal phase support. , 2023, , 275-285.		0